Human IFN-γ ELISpot Pair
Product Specifications
- Catalogue N°
- 869.060.010 - 10 x 96 tests
- Target species
- Human
- Specificity
- Recognizes natural human IFN-g
- Cross Reaction
- No cross reactivity with other human cytokines. Cross reactivity with simian IFN-g.
- Kit Content
- Diaclone ELISpot matched antibody pairs are extensively validated and include pre-titrated capture antibody and biotinylated detection antibody. Antibodies are supplied in quantities sufficient for 10 x 96 samples.
- Synonym
- IFN-g
- IFN-gamma
References
- Andres, C. et al., J. Virol.,2015;89(18): 9189-9199 - Pubmed link
- Bricaire, F. et al., Bull Acad Natl Med.,2006;190(4-5):1035-46; discussion 1046-9 - Pubmed link
- Carcelain G. et al., J. Virol., 2001; 75(1) : 234 - 241 - Pubmed link
- García, F. et al., Science Translational Medicine, 2013;5:166ra2 - Pubmed link
- Garcia, F. et al.,The Journal of Infectious Disease,2011; 203(4): 473-478 - Pubmed link
- Guihot, A. et al., Blood,2007; 111:1387-1395 - Pubmed link
- Guihot, A. et al., J Infect Dis.,2006;194(8):1078-88 - Pubmed link
- Mohty M. et al., Bone Marrow Transplant., 2004;33(8): 839-846 - Pubmed link
- Samri A. et al., J. Virol., 2000; 74(19): 9306 - 9312 - Pubmed link
- Scarpellini P. et al. J. Clin. Microbiol., 2004; 42(8): 3469 - 3474 - Pubmed link
- Speiser D.E. et al., J. Clin. Invest., 2005; 115(3): 739 - 746 - Pubmed link
- Speiser, D. E. et al., PNAS,2008; 105(10): 3849-3854. - Pubmed link
- Terrazzini,N. et al.,J Infect Dis.,2018 May 25;217(12):1997-2007 - Pubmed link
- Vogt, A. et al., J. Immunol.,2008; 180(3): 1482-1489. - Pubmed link
- Wang, X.-F. et al., J. Immunol.,2008; 181(1): 431-439. - Pubmed link
- Nakid-Cordero, C. et al., PLoS One. 2019 Oct 22;14(10):e0224211. - Pubmed link
- Scholzen, A. et al., Front Immunol. 2019 Feb 15;10:207. - Pubmed link
- Frange, P. et al., Front Immunol. 2021; 12: 662894. - Pubmed link
- Pilmis, B. et al., Infect Dis Now. 2022 Mar; 52(2): 68–74. - Pubmed link
Related products
- 855.000.000 - Anti-Human IFN-γ Azide Free
- 855.001.019 - Anti-Human IFN-γ FITC Conjugated
- 855.002.019 - Anti-Human IFN-γ PE Conjugated
- 879.000.001 - Anti-Human IFN-γ Capture Antibody
- 879.000.002 - Anti-Human IFN-γ Detection Antibody
- 850.900.048 - Human IFN-γ High Sensitivity ELISA Kit
- 860.050.048 - Murine IFN-γ ELISA Kit
- 865.010.048 - Rat IFN-γ ELISA Kit
- 950.000.048 - Human IFN-γ ELISA Kit
- 851.560.001 - Human IFN-γ ELISA Set
- 861.050.001 - Murine IFN-γ ELISA Set
- 872.000.001 - Rat IFN-γ ELISA Set
- 856.051.001 - Human IFN-γ ELISpot Set
- 856.051.001PC - Human IFN-γ ELISpot Kit
- 862.031.001 - Murine IFN-γ ELISpot Set
- 862.031.001PC - Murine IFN-γ ELISpot Kit
- 867.011.001 - Rat IFN-γ ELISpot Set
- 867.011.001PC - Rat IFN-γ ELISpot Kit
- 870.050.010 - Murine IFN-γ ELISpot Pair
- 871.020.010 - Rat IFN-γ ELISpot Pair
- 853.670.000 - Anti-Human IFN-γ Azide Free
- 856.051.001PCS - Human IFN-γ EasySplit ELISpot Kit
- 862.031.001PCS - Murine IFN-γ EasySplit ELISpot Kit
BACKGROUND
Different populations of T-cells secrete differing patterns of cytokines that ultimately lead to different immune responses. IFNg production is a key function of Th1, CD8+ CTLs and also NK cells. IFNg is a cytokine critical for cell mediated immunity against viral and intracellular bacterial infections and is involved in the inflammatory response following secretion via macrophage activation and stimulation of antibody secretion. IFNg is the hallmark effector cytokine of Th1 and therefore is an excellent marker for identifying a host response to intracellular pathogens.
IFNg is produced during infection by T cells of the cytotoxic/suppressor phenotype (CD8) and by a subtype of helper T cells, the Th1 cells. Th1 cells secrete IL-2, IL-3, TNFa and IFNg, whereas Th2 cells mainly produce IL-3, IL-4, IL-5, and IL-10, but little or no IFNg. IFNg preferentially inhibits the proliferation of Th2 but not Th1 cells, indicating that the presence of IFNg during an immune response will result in the preferential proliferation of Th1 cells.
In addition, IFNg has several properties related to immunoregulation. IFNg is a potent activator of mononuclear phagocytes, and activates macrophages to kill tumor cells by releasing reactive oxygen intermediates and TNFa. IFNg induces or augments the expression of MHC antigens on macrophages, T and B cells and some tumor cell lines. On T and B cells IFNg promotes differentiation. It enhances proliferation of activated B cells and can act synergistically with IL-2 to increase immunoglobulin light-chain synthesis.
The role of IFNg as a disease marker has been demonstrated for a number of different pathological situations including, viral infection, Autoimmune disease, transplant rejection, Diabetes and allergy .
Version 16 - 09.22
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.